TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06514547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conjugate Pneumococcal Vaccine 20 (PCV20)
Description: Vaccine
Study: NCT04843761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir Placebo
Description: Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir Placebo
Description: Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aviptadil
Description: Administered by IV infusion over 12 hours per day for 3 days. Participants are no longer being randomized to this intervention.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Aviptadil
Description: Administered by IV infusion over 12 hours per day for 3 days. Participants are no longer being randomized to this intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aviptadil Placebo
Description: Commercially available 0.9% sodium chloride solution. Administered by IV infusion over 12 hours per day for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aviptadil Placebo
Description: Commercially available 0.9% sodium chloride solution. Administered by IV infusion over 12 hours per day for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid
Description: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
Study: NCT06050694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glofitamab
Description: Glofitamab 2.5 mg Cycle 3 Day 8 and 10 mg on Day 15 Cycles 3-6
Study: NCT05582993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand Factor (rVWF)
Description: rVWF administered by intravenous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand Factor (rVWF)
Description: rVWF administered by intravenous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand Factor (rVWF)
Description: rVWF administered by intravenous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADVATE
Description: ADVATE administered by intravenous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADVATE
Description: ADVATE administered by intravenous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADVATE
Description: ADVATE administered by intravenous injection.
Study: NCT06444581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Super Skills Schools
Description: Super Skills Structured and manualized intervention with a manual for the therapist and a workbook for the children. The intervention will be administered by Super Skills-trained clinical psychologists. Sessions will take place once a week for twelve weeks, with each session lasting approximately fifty minutes. The program includes emotional education and social skills training. These contents are learned through playful exercises, activities, readings and role-playing. The intervention modality will be face-to-face.
Study: NCT05494996

Intervention type: OTHER
Intervention: Questionnaires set
Description: Participants will be asked to respond to the demographic information sheet and the five-item relationship satisfaction scale(RS5) .
Study: NCT04848272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Monoclonal antibody that targets active plasma kallikrein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Monoclonal antibody that targets active plasma kallikrein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Monoclonal antibody that targets active plasma kallikrein

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline control
Description: Saline control
Study: NCT05547126

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: It is currently known that Transcranial Direct Current Stimulation (tDCS) can modulate cortical activity, being considered an important resource in the treatment of sequelae resulting from stroke.~Cognitive motor dual-task training (CMDT) is a type of cognitive rehabilitation training at the same time as exercise rehabilitation therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: It is currently known that Transcranial Direct Current Stimulation (tDCS) can modulate cortical activity, being considered an important resource in the treatment of sequelae resulting from stroke.~Cognitive motor dual-task training (CMDT) is a type of cognitive rehabilitation training at the same time as exercise rehabilitation therapy.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: It is currently known that Transcranial Direct Current Stimulation (tDCS) can modulate cortical activity, being considered an important resource in the treatment of sequelae resulting from stroke.~Cognitive motor dual-task training (CMDT) is a type of cognitive rehabilitation training at the same time as exercise rehabilitation therapy.
Study: NCT06407050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 hours of physical inactivity
Description: A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day participants need to take 600 steps hourly for 8 hours from 7 am to 3 pm and another 2,000 steps between 3:40 pm to 4 pm. Participant will then stay inactive from 4 pm to 8 pm and do a cycling for one hour in the lab. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8 hours of physical inactivity
Description: A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day participants need to take 600 steps hourly for 4 hours from 7 am to 11 am and then 2,000 steps between 11:40 am to 12 pm. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. Participant will then stay inactive from 12 pm to 8 pm and do a cycling for one hour in the lab. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12 hours of physical inactivity
Description: A pedometer will be worn by participants during the whole trial. Steps will be monitored. Participants will be required to reach 8,500 steps per day for the first 2 days. On the third day, participant will take 2,000 steps between 7:40 am to 8 am and then stay inactive from 8 am to 8 pm. During the inactivity period, participants will remain seated and steps are only allowed for food, water, and bathroom use. Right after the inactivity intervention, participant will do a 1-hr cycling in lab. A 3 day food log will be given to participants to log in their diet. Participant will be asks to mimic the diet between trials. A Fitbit will be worn by participants to record the sleep hours during the trial.
Study: NCT06172647

Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy
Description: Endoscopic exploration of the colon (colonoscopy) for standard clinical practice (study of chronic watery diarrhoea, treatment of colon adenomas or population screening with a positive faecal occult blood test)

Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy
Description: Endoscopic exploration of the colon (colonoscopy) for standard clinical practice (study of chronic watery diarrhoea, treatment of colon adenomas or population screening with a positive faecal occult blood test)

Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy
Description: Endoscopic exploration of the colon (colonoscopy) for standard clinical practice (study of chronic watery diarrhoea, treatment of colon adenomas or population screening with a positive faecal occult blood test)

Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy
Description: Endoscopic exploration of the colon (colonoscopy) for standard clinical practice (study of chronic watery diarrhoea, treatment of colon adenomas or population screening with a positive faecal occult blood test)
Study: NCT05484011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: odetiglucan
Description: Odetiglucan is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Odetiglucan acts as a Pathogen-Associated Molecular Pattern (PAMP).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: odetiglucan
Description: Odetiglucan is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Odetiglucan acts as a Pathogen-Associated Molecular Pattern (PAMP).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-1140
Description: A fully human agonist anti-CD40 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX-1140
Description: A fully human agonist anti-CD40 monoclonal antibody
Study: NCT05328492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iVAPS-AE
Description: Patients randomised to this intervention will commence home NIV in iVAPS-AE mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ST-mode
Description: Patients randomised to this intervention will commence home NIV in ST-mode according to the clinical operating procedures used at the Respiratory and Sleep Science Department. Patients will follow a NHS standard care pathway as described in the study protocol.
Study: NCT05912192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elonide Nasal Spray
Description: 50mcg/dose One puff for each nostrils twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasonex Nasal Spray
Description: 50mcg/dose One puff for each nostrils twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 50mcg/dose of 0.9% sodium chloride One puff for each nostrils twice daily
Study: NCT06269042

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: The subjects will perform deep inspirations against a threshold device with varying resistances,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The subjects will perform deep inspirations against a threshold device with varying resistances,
Study: NCT05199935

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Control video on healthy pregnancy
Study: NCT06156995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Acupuncture at Zhongliao Point to Stimulate Sacral Nerve
Description: Using 0.30mm × 75mm millineedle (produced by Suzhou Medical Equipment Factory, Huatuo brand) deeply punctures the Zhongliao acupoint to reach the sacral nerve. The acupuncture needle is connected using the MuhiStim Sensor nerve stimulator produced by Pajunk in Germany. Connect the positive pole to the left Zhongliao hole and the negative pole to the right Zhongliao hole. The frequency, current, and pulse width of sacral nerve electrical stimulation are 2 Hz, 5mA, and 0.1 ms, respectively.Electroacupuncture stimulates the sacral nerve for 30 minutes, once a day, five times a week. After the treatment, rest for two days before starting the next treatment. Five sessions are considered as one course of treatment, with a total of four courses for four consecutive weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Mosapride Tablets
Description: Mosapride citrate tablets (produced by Lunan Beite Pharmaceutical Co., Ltd., with the national drug approval number H19990317), oral administration, 5mg once, three times a day, taken before meals. 5 days is one course of treatment, with 2 days of rest during the treatment period. The total treatment period is 4 weeks, with a total of 4 courses.
Study: NCT05674825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted agent
Description: The Molecular Tumor Board (MTB) will suggest molecularly targeted matched treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted agent
Description: The Molecular Tumor Board (MTB) will suggest molecularly targeted matched treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted agent
Description: The Molecular Tumor Board (MTB) will suggest molecularly targeted matched treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care agent
Description: Subjects will receive treating physician's choice of traditional systemic therapy treatment for their malignancy, defined by National Comprehensive Cancer Network (NCCN) guidelines and/or tumor board recommendation(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care agent
Description: Subjects will receive treating physician's choice of traditional systemic therapy treatment for their malignancy, defined by National Comprehensive Cancer Network (NCCN) guidelines and/or tumor board recommendation(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care agent
Description: Subjects will receive treating physician's choice of traditional systemic therapy treatment for their malignancy, defined by National Comprehensive Cancer Network (NCCN) guidelines and/or tumor board recommendation(s).
Study: NCT05772728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen
Description: CAM regimen (every 21 days as a treatment cycle). Cetapenem 20 mg orally twice weekly Azacitidine 75 mg/m2 subcutaneously d1-7 Mitoxantrone liposomes 20 mg/m2 intravenous d6
Study: NCT06542822

Intervention type: DRUG
Intervention: Ferric derisomaltose
Description: See group descriptions
Study: NCT05863780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carpal bone mobilization
Description: Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest- 3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexor retinaculum stretch
Description: Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time,-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carpal bone mobilization and flexor retinaculum stretch
Description: 1. Carpal bone mobilization 5 repetition/1 set lasted for 15 secs followed by 10 secs of rest.3 sessions on alternate days per week for 04 weeks.~2. Flexor retinaculum stretch 5 repetitions/ 1 set held for 60 secs at a time-3 sessions on alternate days per week for 04 weeks.~Total of 12 sessions will be given, each consisting of 45 mins.
Study: NCT05022121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported Biopsychosocial Self-Management (SBSM)
Description: Participants receive training and instruction in skills to engage in healthy physical, psychological, and social self-management behaviors. This will be accomplished through 6-12 sessions with a trained chiropractor or physical therapist. Patients will receive training and instruction in exercises targeting posture, strength, stabilization, and mobility based on their individual needs. They will learn psychological strategies including problem solving and cognitive restructuring to address unhelpful thoughts and emotions. Social strategies include pleasant activity planning with a social focus, and communication techniques for navigating relationships to garner support for self-sufficiency. Other elements include providing key evidence based information about BRLP and spinal manipulation therapies (SMT). SMT will include manipulation, mobilization and soft-tissue treatment. Other intervention elements include enablement, persuasion, and resources and materials to support the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Care
Description: Medical care will be comprised of primarily medication management, which is a standard first-line approach for back-related leg pain in primary care. Choice of medications is informed by the current evidence and the American College of Physicians guidelines on noninvasive treatment for LBP which balances evidence for risks and benefits when making recommendations. Decisions regarding medication selection will be made collaboratively between the study provider and patient after a discussion of risk/benefit profiles and patient preferences, including prior response. Study providers licensed to prescribe FDA-approved medications will call-in the prescription for the medication of choice to the participant's preferred pharmacy, as is typical in clinical practice.
Study: NCT04975867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted therapeutic hypothermia
Description: Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted therapeutic normothermia
Description: Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.
Study: NCT05828030

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: the patient receives HFNC after randomization. All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen mask
Description: All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
Study: NCT05623774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib Mesylate
Description: 400mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib Mesylate
Description: 400mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib Mesylate
Description: 400mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IkT-001Pro
Description: 100mg or 400mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IkT-001Pro
Description: 100mg or 400mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IkT-001Pro
Description: 100mg or 400mg tablet
Study: NCT04869865

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 9-day detoxification cleanse and 1 week of pre-cleanse transition
Description: Subjects will participate in the full 9-day Springtime Home Cleanse, including the week prior to a pre-cleanse transition period. The cleanse includes a transition week, 9 days of a monodiet, internal oleation with ghee, external oleation, herbs, purgation, and an enema. During this time, subjects will also attend daily online meetings on Facebook Live throughout the cleanse and on AyurPrana's AyurLearn online portal to participate in guided mediation and yoga. Subjects will also use these platforms to access daily cleanse instructions and journaling topics.
Study: NCT06724861

Intervention type: OTHER
Group type: OTHER
Intervention: Explicit Sensory Retraining for the lower extremities
Description: Sensory retraining of detection, discrimination, quantification of a stimuli and recognition of stimuli and objects with the leg and mainly with the foot. Top-down awareness of bottom-up sensory experience in the treatment session and in everyday life.

Intervention type: OTHER
Group type: OTHER
Intervention: Explicit Sensory Retraining for the lower extremities
Description: Sensory retraining of detection, discrimination, quantification of a stimuli and recognition of stimuli and objects with the leg and mainly with the foot. Top-down awareness of bottom-up sensory experience in the treatment session and in everyday life.

Intervention type: OTHER
Group type: OTHER
Intervention: no treatment
Description: Usual care

Intervention type: OTHER
Group type: OTHER
Intervention: no treatment
Description: Usual care
Study: NCT06722690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eTSF
Description: eTSF is a smartphone app intervention featuring culturally relevant content aimed at supporting Latinx young adults with alcohol use disorder in participating in 12-step groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials
Description: Educational materials on drinking problems and a list of local/online AA meetings.
Study: NCT06722547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard PR
Description: PLB, ACBT, Aerobic exercise, Education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard PR plus Respiratory Muscle Stretching
Description: Standard PR plus Respiratory Muscle Stretching (RMS)
Study: NCT06230705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided management
Description: Guided Management
Study: NCT05072938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucotra SR Tablet 150mg
Description: Rebamipide/Nizatidine Combination Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axid Capsule 150mg
Description: Nizatidine Monotherapy